This triple-pathway may increase fat burning and reduce appetite more than current GLP-1 medicines
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of pharmacological agents with both glucose-lowering and weight-reducing effects
GLP-1sthat is, the class of drugs that includes semaglutide, packaged in brand-name form as Ozempic and Wegovy, and tirzepatide, like Mounjaroact on receptors in the body, and they improve insulin resistance, explains Judi Chervenak, MD, a reproductive endocrinologist at Montefiore with a clinical focus on menopause
Depending on the new medication prescribed, your provider may recommend a gradual tapering of Ozempic to minimize potential withdrawal symptoms or fluctuations in blood sugar levels
Trossbach SV, Bader V, Hecher L, Pum ME, Masoud ST, Prikulis I, et al
You're not being controlled by your appetite." ***Please sign up for CBN Newsletters and download the CBN News app to ensure you receive the latest news from a distinctly Christian perspective.*** That's because these drugs mimic natural gut hormones that target brain receptors, which can communicate messages and changes to the body
